Biopsies from metastatic Clear Cell Renal Carcinoma before or after treatment with nivolumab

ABSTRACT: Tumor core needle biopsies from kidney or metastatic sites obtained at trial enrollment i.e. Screen and/or at Cycle 2 Day 8 (i.e.Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) of nivolumab (BMS-936558,MDX-1106) on Bristol-Myers Squibb clinical trial protocol CA209-009.

INSTRUMENT(S): Gene Titan

ORGANISM(S): Homo sapiens

SUBMITTER: Petra Ross-Macdonald 

PROVIDER: E-MTAB-3218 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress